Hormonal
In utero exposure to maternal hyperglycemia (gestational diabetes or elevated glucose levels) independently increases the risk of abnormal glucose tolerance, obesity, and higher blood pressure in offspring by age 7, independent of maternal pre-pregnancy BMI, birth weight, or childhood obesity.
If a mother has gestational diabetes or elevated blood sugar during pregnancy, her child is at a higher risk for metabolic issues like obesity and glucose intolerance by age 7, regardless of the child's birth weight. This risk is biological and programmed in utero. Parents should be aware of this increased risk and prioritize regular metabolic health monitoring (blood pressure, glucose, weight) for their children, especially if there is a family history of diabetes.
Maternal hyperglycemia in pregnancy is independently associated with offsprings’ risk of abnormal glucose tolerance, obesity, and higher BP at 7 years of age.
Why this rating
Prospective cohort study with a large sample size (n=970) and rigorous adjustment for confounders, though observational design limits causal inference compared to RCTs.
Source
In Utero Exposure to Maternal Hyperglycemia Increases Childhood Cardiometabolic Risk in Offspring
Wing Hung Tam et al. · Diabetes Care · 2017
DOI 10.2337/dc16-2397
More from this paper
- The effect of maternal hyperglycemia on childhood adiposity (overweight/obesity and sum of skinfold thickness) is sex-specific, being significant in girls but not in boys.Good
- Maternal 1-hour glucose levels during pregnancy are specifically associated with an increased risk of childhood prehypertension or hypertension, independent of other glucose measures.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →